MMDA-2

MMDA-2

Systematic (IUPAC) name
1-(6-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
Clinical data
Legal status	Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Routes of administration	Oral, Insufflated, Rectal
Identifiers
CAS Number	23693-18-7
ATC code	none
PubChem	CID: 90966
ChemSpider	82147
Chemical data
Formula	C11H15NO3
Molecular mass	209.24 g/mol
SMILES O1c2cc(c(OC)cc2OC1)CC(N)C

MMDA-2 (2-methoxy-4,5-methylenedioxyamphetamine) is a psychedelic drug of the amphetamine class. It is closely related to MMDA and MDA.

Alexander Shulgin was likely the first to synthesize MMDA-2. In his book PiHKAL, the dose is listed as 25–50 mg, and the duration is listed as 8–12 hours. Shulgin reports that MMDA-2 produces effects such as enhanced awareness, empathy, and visual facilitation and distortion, as well as some side effects like gastrointestinal upset and appetite loss. He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose.

Scientific research has shown that MMDA-2, unlike MMDA, but similarly to 6-methyl-MDA, is only very weak at inducing the release of serotonin or dopamine, and accordingly, does not produce amphetamine-appropriate responding in animals in drug discrimination studies. Instead, MMDA-2 is likely to act as a pure 5-HT₂ receptor agonist similarly to the DOx series of compounds, with activation of the 5-HT_2A receptor conferring its psychedelic effects.

MMDA-2 has been sold as a designer drug in Japan.

See also

• 6-Methyl-MDA
• Methyl-MMDA-2
• MMDA
• MDA
• Lophophine

External links

• Erowid - PiHKAL entry for MMDA-2
• Isomerdesign - PiHKAL entry for MMDA-2